FGF23 and inflammation-a vicious coalition in CKD.

Fibroblast Growth Factor-23 Fibroblast Growth Factors Humans Hypophosphatemia, Familial Inflammation Renal Insufficiency, Chronic

Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
10 2019
Historique:
received: 06 05 2019
revised: 09 05 2019
accepted: 13 05 2019
entrez: 24 9 2019
pubmed: 24 9 2019
medline: 13 6 2020
Statut: ppublish

Résumé

High serum concentrations of the phosphaturic hormone, fibroblast growth factor 23 (FGF23), contribute to various tissue injuries. In chronic kidney disease, the sources of FGF23 and the stimuli that control FGF23 production differ from those in the physiologic scenario. Mediators of inflammation are intensively studied as potential factors that contribute to FGF23 elevations and thereby might function as drug targets to lower FGF23 levels. The present study focuses on tumor necrosis factor.

Identifiants

DOI: 10.1016/j.kint.2019.05.018 PMID: 31543148
pubmed: 31543148
pii: S0085-2538(19)30593-9
doi: 10.1016/j.kint.2019.05.018
pii:
doi:

Substances chimiques

FGF23 protein, human 0
Fibroblast Growth Factors 62031-54-3
Fibroblast Growth Factor-23 7Q7P4S7RRE

Types de publication

Journal Article Comment

Langues

eng

Sous-ensembles de citation

IM

Pagination

813-815

Subventions

Organisme : NIDDK NIH HHS
ID : F31 DK117550
Pays : United States

Commentaires et corrections

Type : CommentOn

Informations de copyright

Copyright © 2019 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Auteurs

Brian Czaya (B)

Division of Nephrology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.

Christian Faul (C)

Division of Nephrology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA. Electronic address: cfaul@uabmc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Facteur-23 de croissance des fibroblastes › FGF23 and inflammation-a vicious coalition in CKD.
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Facteurs de croissance fibroblastique › FGF23 and inflammation-a vicious coalition in CKD.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › FGF23 and inflammation-a vicious coalition in CKD.
questionsmedicales.fr › Maladies métaboliques et nutritionnelles › Maladies métaboliques › Troubles du métabolisme du phosphore › Hypophosphatémie › Hypophosphatémie familiale › FGF23 and inflammation-a vicious coalition in CKD.
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › FGF23 and inflammation-a vicious coalition in CKD.
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Insuffisance rénale chronique › FGF23 and inflammation-a vicious coalition in CKD.